| Original language | English (US) |
|---|---|
| Pages (from-to) | 928-930 |
| Number of pages | 3 |
| Journal | Journal of the American Academy of Dermatology |
| Volume | 83 |
| Issue number | 3 |
| DOIs | |
| State | Published - Sep 2020 |
ASJC Scopus subject areas
- Dermatology
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Journal of the American Academy of Dermatology, Vol. 83, No. 3, 09.2020, p. 928-930.
Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Real-world experience with mechlorethamine gel in patients with mycosis fungoides-cutaneous lymphoma
T2 - Preliminary findings from a prospective observational study
AU - Kim, Ellen J.
AU - Geskin, Larisa
AU - Guitart, Joan
AU - Querfeld, Christiane
AU - Girardi, Michael
AU - Musiek, Amy
AU - Mink, David R.
AU - Williams, Michael J.
AU - Angello, James T.
AU - Bailey, William L.
N1 - Funding Information: Funding sources: This study was supported by Helsinn Therapeutics (US), Inc. Role of the funder: Design and conduct of the study; collection, management, analysis, and interpretation of data; and preparation, review, or approval of the manuscript. All authors made the decision to submit the manuscript for publication.Conflicts of interest: Dr Kim has received grant funding from Helsinn, Galderma, Kyowa Kirin, Medimmune, and Soligenix; consulted for Helsinn and the PROVe Scientific Committee, Galderma, and WebMD; and served on an advisory board for Seattle Genetics. Dr Geskin has received grant funding and has consulted for Helsinn. Dr Guitart has received grant funding and had consulted for Helsinn, received grant funding from Galderma, Medivir, and Soligenix, and has consulted for Miragen and LEO Pharma. Dr Querfeld has consulted for Miragen, Helsinn, Mallinckrodt, Medivir, and Kyowa Kirin and received grant funding from STOP Cancer, the Leukemia & Lymphoma Society, Trillium, and Celgene Corp. Dr Girardi has consulted for Helsinn, Mallinckrodt, Transimmune, and Sanofi and received grant funding from Helsinn, Soligenix, and AbbVie. Dr Musiek has received grant funding and consulted for Helsinn, Elorac, Kyowa Kirin, Soligenix, and Pfizer; served on advisory board for Helsinn, Kyowa Kirin, and Seattle Genetics, and served on a speakers bureau for Helsinn. Mr Mink and Dr Williams are employed by ICON Commercialization & Outcomes. Dr Angello and Dr Bailey are employed by Helsinn Therapeutics (US), Inc. Funding Information: Conflicts of interest: Dr Kim has received grant funding from Helsinn , Galderma , Kyowa Kirin , Medimmune , and Soligenix ; consulted for Helsinn and the PROVe Scientific Committee , Galderma , and WebMD ; and served on an advisory board for Seattle Genetics. Dr Geskin has received grant funding and has consulted for Helsinn . Dr Guitart has received grant funding and had consulted for Helsinn , received grant funding from Galderma , Medivir , and Soligenix , and has consulted for Miragen and LEO Pharma . Dr Querfeld has consulted for Miragen , Helsinn , Mallinckrodt , Medivir , and Kyowa Kirin and received grant funding from STOP Cancer , the Leukemia & Lymphoma Society , Trillium , and Celgene Corp. Dr Girardi has consulted for Helsinn , Mallinckrodt , Transimmune , and Sanofi and received grant funding from Helsinn , Soligenix , and AbbVie . Dr Musiek has received grant funding and consulted for Helsinn , Elorac , Kyowa Kirin , Soligenix , and Pfizer ; served on advisory board for Helsinn , Kyowa Kirin , and Seattle Genetics , and served on a speakers bureau for Helsinn . Mr Mink and Dr Williams are employed by ICON Commercialization & Outcomes. Dr Angello and Dr Bailey are employed by Helsinn Therapeutics (US), Inc. Funding Information: Funding sources: This study was supported by Helsinn Therapeutics (US), Inc. Role of the funder: Design and conduct of the study; collection, management, analysis, and interpretation of data; and preparation, review, or approval of the manuscript. All authors made the decision to submit the manuscript for publication.
PY - 2020/9
Y1 - 2020/9
UR - http://www.scopus.com/inward/record.url?scp=85079901033&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85079901033&partnerID=8YFLogxK
U2 - 10.1016/j.jaad.2019.12.070
DO - 10.1016/j.jaad.2019.12.070
M3 - Article
C2 - 32089294
AN - SCOPUS:85079901033
SN - 0190-9622
VL - 83
SP - 928
EP - 930
JO - Journal of the American Academy of Dermatology
JF - Journal of the American Academy of Dermatology
IS - 3
ER -